MNCM aspirin requirements and 2018 aspirin guidelines

The aspirin guidelines released in 2018 by the American College of Cardiology relate to the use of aspirin for the primary prevention of a cardiovascular event (e.g., heart attack, stroke) if the potential benefit outweighs bleeding risk after clinician-patient risk discussion. Daily aspirin is indicated for secondary prevention when cardiovascular disease is known or an event has occurred.

The aspirin/anti-platelet component in the Optimal Diabetes Care and Optimal Vascular Care measures remains as follows:

aspirin or anti-platelet expected for all patients with ischemic vascular disease unless a contraindication is documented.
in the diabetes measure, those patients with the field “Patient has IVD” = 0 (No) are given a “free pass” for the component because they do not have IVD; those patients with the field “Patient has IVD” = 1 (Yes) are expected to be on daily aspirin or anti-platelets unless a contraindication is documented.

Reference: ACC's Clinician Guide to the ABCs of Primary and Secondary Prevention of Atherosclerotic Cardiovascular Disease article: https://www.acc.org/latest-in-cardiology/articles/2018/03/30/18/34/clinician-guide-to-the-abcs

acc american college of cardiology anti-platelet aspirin diabetes guideline vascular

Creation date: 3/27/2019 3:07 PM Updated: 11/13/2020 1:12 PM

Files		Sort by Name Sort by Date
	image001.jpg 3.2 KB
	image002.jpg 1.1 KB
	image003.jpg 1.1 KB
	image004.jpg 1.1 KB

This category is for questions related to the Optimal Diabetes Care and the Optimal Vascular Care clinical quality measures.